Abatacept Therapy in Rheumatoid Arthritis With Interstitial Lung Disease

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

(2011) D. E. Furst et al.   ANNALS OF THE RHEUMATIC DISEASES

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients

(2011) T. Koike et al.   ANNALS OF THE RHEUMATIC DISEASES

Interstitial lung disease following certolizumab pegol

(2011) F. Pearce et al.   RHEUMATOLOGY

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review

(2011) A. V. Hadjinicolaou et al.   RHEUMATOLOGY

Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases

(2011) Roberto Perez-Alvarez et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

The use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis

(2010) K. Neff et al.   THORAX

Abatacept and serious respiratory infections in patients with previous lung disease

(2008) Karla L. Miller et al.   CLINICAL RHEUMATOLOGY

Abatacept in the treatment of rheumatoid arthritis

(2008) Maya H Buch et al.   ARTHRITIS RESEARCH & THERAPY